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Abstract
Background: High resolution anoscopy (HRA) examination is regarded as the best method for the management of
anal high grade squamous intraepithelial lesions to prevent anal squamous carcinoma. However, little is known
about the acceptability of this procedure. This analysis looks at patient experience of HRA examination and ablative
treatment under local anaesthetic.
Methods: Patients took part in anonymised feedback of their experience immediately after their HRA examinations
and/or treatments. A standard questionnaire was used that included assessment of pain and overall satisfaction
scores as well as willingness to undergo future HRA examinations.
Results: Four hundred four (89.4%) responses were received and all responses were analysed. The group consisted
of 119 females (29.4%) and 261 males (64.6%) with median age of 45 years (IQR = 19) and 45 years (IQR = 21)
respectively, and included 58 new cases, 53 treatment cases and 202 surveillance cases. 158 patients (39.1%) had at
least one biopsy during their visits. The median pain score was 2 [Inter Quartile Range (IQR) 3] on a visual analogue
scale of 0 to 10, where 0 indicated no pain / discomfort and 10 indicated severe pain. The median pain score was 2
(IQR 2) in men and 4 (IQR = 3) in women [Dunn’s Test = 4.3, p < 0.0001] and 3 (IQR 4.5) in treatment cases.
Problematic pain defined as a pain score of ≥7 occurred more frequently in women (14%) than in men (6%), [Chi
square test (chi2) = 5.6, p = 0.02]. Patient satisfaction with the care they received, measured on a scale of 0 (not
happy) to 10 (very happy) found the median score to be 10 with 76% reporting a score of 10. Out of 360
responses, 98% of women and 99% of men said that they would be willing to have a future HRA examination.
Conclusions: In this cohort, the overall pain scores were low and similar across appointment types. However,
women had a higher pain score, including troublesome pain levels. Despite this, both women and men were
equally satisfied with their care and were willing to have a future examination. The results of the analysis show that
the procedure is acceptable to patient groups. A small number of women may need general anaesthesia for their
examinations/treatment.
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Background
High risk human papillomavirus (HPV) infections are as-
sociated with lower anogenital tract cancers [1]. Rates of
anal cancer and associated mortality rates have been pre-
dicted to increase over the next two decades in the United
Kingdom [2]. High resolution anoscopy (HRA) consists of
the examination of the anal canal and perianus using a
magnifying device with a good light source (colposcope),
after application of 5% acetic acid solution to highlight ab-
normalities that indicate anal neoplasia. HRA and directed
biopsy is regarded as the definitive method for the detec-
tion of high grade squamous intraepithelial lesion (HSIL)
in the anal canal and perianus [3] (collectively called anal,
hereafter). Anal HSIL is considered as the precursor lesion
for anal squamous cell carcinoma and the detection of
anal HSIL will enable treatment or close monitoring to
help with cancer prevention efforts [4]. Like colposcopy,
HRA is a specialist skill that is learned over time [5]. Re-
cently, the minimum standards for the practice of HRA
have been published [6]. We do not yet have published
data on the formal assessment of patient experience from
those undergoing HRA examination and treatment that
include both men and women. A previous study reported
on patient experience of men in a screened population [7].
We conducted a study of patient experience at Home-
rton anal neoplasia service (HANS), a tertiary referral
unit, run by a multidisciplinary team in the United King-
dom. Patients are referred from across the UK for anal
and perianal HSIL diagnosis and treatment. Additionally,
women with lower anogenital tract HSIL or suspected
HSIL are referred to HANS for further management.
The aim of the study was to establish if HRA, including
biopsy and HRA-guided treatment, is acceptable as a
procedure to a UK population of men and women.
Methods
During the period between October 2015 and August
2016, after obtaining institutional approval, patients at-
tending HANS were asked to provide their feedback.
Following verbal consent, patients were examined in the
outpatient (office) setting in the dorsal lithotomy pos-
ition with an adjustable bed. Patient assessments were
made after 5% acetic acid applications to the zones to be
inspected. Women had multizonal assessments that in-
cluded examination of the cervix, vagina, vulva, perianus
and the anal canal. Men had examination of the perianus
and anal canal, unless they had genital symptoms or pre-
vious history of penile neoplasia, in which case genital
examinations were additionally conducted. All biopsies
were obtained after the administration of Citanest 3%
with octapressin (injection, prilocaine hydrochloride
30 mg/mL, felypressin 0.03 unit/mL; Aston Pharma
Trading ltd., 3016 Lake drive, Citywest Business campus,
Dublin 24, Ireland) by injection, by using a Tischler
biopsy forceps. Ferric subsulphate (Monsel’s solution)
was then applied to the biopsy site for haemostasis. Pa-
tients attending for treatment with laser ablation applied
EMLA™ cream 5% (contains lidocaine and prilocaine) to
the treatment areas prior to arrival in the office. Treat-
ment patients underwent HRA assessments to mark out
the areas for treatment, then received local anaesthetic as
above via submucosal or subcutaneous injections, and
underwent treatment with CO2 laser ablation (for perianal
disease) or diode laser ablation (for anal canal disease).
Outpatient-based treatments were limited to disease in-
volving no more than 2 quadrants (50%) of the circumfer-
ence. Using a pre-formatted feedback form (Fig. 1),
patient experience was collated. The questions used in the
feedback form had face validity established with a small
group of patients prior to the data collection. The feed-
back form also included a free text section inviting sugges-
tions for improving the care they received. Duration of
examination was not recorded. However, our clinic ap-
pointments are assigned in such a way that men have
30 min for their consultation and examination, while
women have 1 hour for consultation and examination.
The forms were given immediately after the procedure
to all consecutive patients during the study period by
the nurse. The forms had a visual analogue scale of 0 to
10, where 0 indicated no pain or discomfort at all, and
10 indicated severe pain. The independent clinician and
nurse scores of patient experience of pain were recorded.
The nurse also made a note of the type of patient visit
(assessment vs. follow-up vs. treatment) and the number
of biopsies, if taken. The feedback form also included an
overall satisfaction score; a visual analogue scale with 0
indicating ‘not happy’ and 10 indicating ‘very happy’. Pa-
tients were also asked about their willingness to undergo
HRA examination in the future. Patients were asked to
fill the form in privacy at the Unit’s reception and post
them into a box kept at the reception. The forms were
anonymous and had no patient identifiers other than age
and sex. A retrospective analysis of the data was con-
ducted after Institutional approval (Homerton Hospital
Project number - 2377/2818).
Results
During the period of October 2015 and August 2016,
452 patient attendances were recorded and 404 re-
sponses (89.4%) were received. Of the 404, 119 (29.4%)
were females while 261 (64.6%) were males (24 missing
gender). The median age was 45 years (IQR = 19) in fe-
males and 45 (IQR = 21) in males. There were 58 new
cases, 53 treatment cases and 202 surveillance cases in
the study population (data not entered in 101). 158 cases
(39.1%) had at least one biopsy during their visits and
amongst these patients 85 (54%) had 2 or more.
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From 399 responses, the median pain score was 2
(IQR 3) on a pain scale of 0 to 10, where 0 indicated no
pain or discomfort and 10 indicated severe pain. The
median pain score amongst men was 2 (IQR 2) while in
females was 4 (IQR 3) [Dunn’s Test = 4.3, p < 0.0001].
Overall, 57 patients (14.3%) reported a zero (0) pain
score. In 157 cases who had biopsies during their visit
the pain score was 3 (IQR 3). From 52 patients who had
treatment under local anaesthesia, the pain score was 3
(IQR 4.5). Problematic pain, defined as a pain score of
≥7, occurred in a small number of cases (9%). More
women (14%) reported problematic pain compared to
men (6%) [chi2 = 5.6, p = 0.02]. Further analysis of
problematic pain by visit type did not show significant
differences (chi2 = 5.8, p = 0.06; Table 1). There was no
correlation between the number of biopsies and the pain
score (Spearman’s rho = 0.09, p = 0.14). The pain score
values appeared consistent across patients and clinicians
(Table 2).
Feed-back on overall satisfaction with care received
was obtained on a scale of 0 to 10, where 0 meant ‘not
happy’ with the service while a score of 10 indicated
‘very happy’ with the care. The median score from 368
responses (91.1%) was 10, with 76% reporting a score of
10. Although 24% reported a score of less than 10, only
4% scored 7 or less on happiness with their care. There
were no differences noted between men and women. A
further patient response, that related to ‘the willingness
to a future HRA examination’, was collected. 44 patients
(10.9%) did not answer this question. Of those that
Fig. 1 Patient feed-back form
Table 1 Problematic pain by visit type
Pain /discomfort levels New cases (%) Treatment (%) Surveillance(%) p-value
Low pain < 7 48 (84.2) 45 (86.5) 188 (93.5) 0.06
Problematic pain ≥7 9 (15.8) 7 (13.5) 13 (6.5)
Total 57 52 201
A visual analogue scale was used from 0 to 10, where 0 meant no discomfort or pain, while a score of 10 indicate severe pain. The median pain score from 399
responses was 2 (IQR 3). Problematic pain score is defined as a score of ≥7. Problematic pain (32/399) identified in 6% of men and 14% of women (chi2
5.6, p = 0.02)
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answered, 99% were willing to re-attend. 4 patients were
not (Table 3). No differences were observed between
men and women regarding their willingness (99% of
men and 98% of women) for a future HRA examination.
Discussion
This study reports the immediate feedback on the pro-
cedure of HRA by patients. This procedure is for the de-
tection of anal cancer precursors, and in those at high
risk, needs to be carried out regularly in order to main-
tain surveillance. From the patients who filled out the
relevant section of the survey, the procedure including
taking of biopsies and treatment does appear to be
highly acceptable to them. Current management of anal
HSIL in many areas of the UK involve multiple biopsies
under general anaesthetic, usually without the high-
resolution element to allow targeting of biopsies. HRA in-
volves not only directed biopsies, hence fewer in number,
but is carried out as a no/ local anaesthetic procedure.
Prospective evaluation of a service has the advantage
of ensuring that data collection can be adequately
planned, and pain assessment is contemporaneous and
is more likely to be complete. By employing this method,
we had an excellent response rate to this evaluation.
There is an increasing trend in healthcare evaluation
to ensure that patients’ views and opinions are taken
into account http://www.healthknowledge.org.uk/public-
health-textbook/research-methods/1c-health-care-evalu-
ation-health-care-assessment/study-design-assessing-ef-
fectiveness (accessed on 5/11/2017). This enables the
analysis of health care provision from the patients’ rather
than healthcare providers’ perspective.
The team at Homerton anal neoplasia service (HANS)
consists of a number of HRA practitioners and this
study reflects the overall performance of the whole team
at HANS. It may be possible for us to bench-mark pa-
tient initiated scores of pain and overall satisfaction of
care for our service, for comparison with other services,
as well as individual practitioners in the future. Patients
at high-risk of anal carcinoma include HIV-positive men
and women [8], those on immune-suppressants such as
renal transplant recipients [9] or patients with systemic
lupus erythematosus [10], and the experience of HRA
examination may vary in different patient groups. Al-
though the HRA practice standards have been published
and will help guide HRA practice, an important element
of assessing performance will be to utilise patient
experience.
Rates of overall questionnaire answering were high but
not all patients completed all the questions. This was
the price of anonymity which we felt was important, in
order to encourage truthful answers. HRA involves in-
timate examination and biopsy under local anaesthetic.
Treatment with laser ablation is one form of ablative
treatment for anal HSIL. In a randomised controlled
study comparing 3 different treatments for anal neopla-
sia, pain was assessed as a side effect to treatment [11].
This study did not distinguish between pain felt during
the procedure and pain that occurred during the recov-
ery period. The pain assessment was retrospective and
not contemporaneous in nature. This study indicates
that pain during the procedure for small office-based ab-
lative procedures under local anaesthetic is acceptable.
In our study, pain scores were essentially similar be-
tween the new cases, treatment cases and those attend-
ing for surveillance. Although ‘problematic pain’ defined
as a pain score of ≥7 was uncommon in this cohort of
Table 2 a and b comparison of pain scores by patients and
clinicians
a
Patient – pain score Nurse assistant – pain score Total
0–3 4–6 ≥ 7
0–3 176 47 7 230
4–6 37 27 6 70
≥7 10 13 2 25
Total 223 87 15 325
b
Patient – pain score HRA clinician - pain score Total
0–3 4–6 ≥ 7
0–3 103 45 6 154
4–6 21 23 4 48
≥7 2 12 4 18
Total 126 80 14 220
Clinicians independently assessed the pain after the procedure and made a
note before handing the form for the patient to fill-in in private. Pain scale
consisted of a numerical visual analogue scale where 0 indicates no pain or
discomfort felt by the patient, while 10 indicates severe pain. There is an asso-
ciation between nurse and patient pain scores (Fisher’s exact test p < 0.001).
Similarly there is an association between clinician’s and patient’s pain scores
(Fisher’s exact test p < 0.001)
Table 3 Willingness for future HRA examinations
Patient category Yes No / unsure No response
After HRA 88.1% (356 / 404) 1% (4 / 404) 10.9% (44 / 404)
After treatment 90.6% (48 / 53) 0 9.4% (5 / 53)
After biopsy (≥1 bx) 87.3% (138 / 158) 1.3% (2 / 158) 11.4% (18 / 158)
Total population = 404. 158 cases (39.1%) had at least one biopsy during their visits and amongst these patients 85 (54%) had 2 or more
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patients, a relatively larger number of women reported
‘problematic pain’. This may relate to the fact that
women have multizonal assessment which includes
examination of the cervix, vagina and vulvar regions at
the same visit as high resolution anoscopy. Previous an-
ecdotal observations suggest that the duration of exam-
ination may determine the level of pain or discomfort
experienced by the patient. The guidelines for inter-
national practice standards recognises the duration of
HRA examination to be important [6]. In the light of
our study’s findings, going forward, we will have a lower
threshold for offering women multizonal HRA assess-
ment under general anaesthesia.
We compared nurse and physician assessment of pain
with patients’ own pain (Table 2a and b). There were 2
patients out of 220 with clinician scores of 0–3, where
the patient recorded a pain score of 7 or more. The op-
posite case, where a high score was assigned by the clin-
ician, but the patient rated this at 0–3 occurred in 6 out
of 220. Nursing evaluation missed severe pain in 10 /
325 and overestimated the pain in 7 / 325. Overall, cor-
relation was fairly accurate with assessment by nurses
and clinicians, hence abandoning the office procedure if
pain is experienced, and rebooking it with sedation or
general anaesthetic is a possible solution for that small
percentage who found the procedure painful.
In our cohort of patients, women were equally sat-
isfied with the care they received as men and almost
all men and women were willing to return for a fu-
ture examination. In a study looking at the psycho-
logical impact of being screened for anal cancer in
HIV-positive men who have sex with men, patients
were more likely to have higher negative impact
scores immediately after being screened, compared to
at other time points such as pre-screen and post-
results [12]. This supports the timing of patient ac-
ceptability feedback that we carried out. Further, pa-
tient’s recollection of their pain experience seems to
rely on the peak intensity of the pain during the pro-
cedure and on the intensity of the pain recorded dur-
ing the last 3 min of the procedure, when measured
for colonoscopy and lithotripsy [13]. This may explain
the occasions when recollected patient pain score did
not correlate with clinician-awarded pain score.
HRA examination is thought to be the ideal method
for the diagnosis of high grade anal neoplasia, through
directed biopsies [14]. It enables a reduction in anal can-
cer progression rates when used for diagnosis, treatment
and surveillance of anal HSIL [15]. Preliminary data in-
dicate that HRA may help to reduce local disease failure
of T1–3 anal cancer cases (TNM classification), when
used for surveillance after treatment [16]. It is note-
worthy that anal HSIL often occur in association with
anal squamous carcinoma, and is believed to be the
precursor to anal carcinoma [4]. HRA surveillance en-
ables detection and adequate treatment of anal HSIL.
This study has several limitations. The National Health
Service in the UK advocates routine collection of patient
feed-back on services. We obtained patient feed-back
over a 10-month period, from patients seeing different
members of staff. Due to the anonymous nature of the
survey, we could not stratify the results according to the
clinician who saw the patient. A small number of pa-
tients (~ 5%) may have attended twice and filled out two
separate forms. This may have ‘amplified’ feed-back re-
sults. Our patient cohort consisted of those who had
HRA only, those who had one or more biopsies, and
those who received treatment. The patients undergoing
treatment and surveillance were by definition groups
who had already attended at least once previously and
thus may bias the results in favour of patients willing to
return for a further examination. However, there were
no significant differences between these three groups in
terms of willingness to return.
No sample size calculations were conducted but we
found a difference in pain scores between men and
women; further studies and replication of the findings are
necessary. The overall response rate was high it was not
100%, and not all patients answered all questions. This
may have reflected a failure of trust in the anonymization
process, leading to a refusal to fill out any deemed to be a
critical or negative response. Both these factors could bias
the results in favour of those who experienced less pain/
were more willing to return. Finally, the feedback audit
was conducted in a tertiary referral unit, and thus the re-
sults may not be generalizable to other populations.
Our results are encouraging in that due to low pain
scores and a high proportion of patients being willing to
return for further visits, we feel that HRA can be sup-
ported as an outpatient procedure, including for small
volume ablative treatments. Access to general anaes-
thetic or sedation may be required for patients, particu-
larly women, who may experience pain during
examination and for larger volume ablative treatments.
Conclusion
High resolution anoscopy (HRA) in the outpatient set-
ting including biopsy and ablative treatment under local
anaesthetic is well-tolerated in men and women in a ter-
tiary referral centre in the UK. Treatment and biopsies
did not impact on the acceptability and pain scores of
the procedure. A small number of people may require
general anaesthetic or sedation in order to undergo the
procedure in comfort. We propose that units currently
carrying out non-high resolution anoscopy with mapping
biopsies under GA consider training in HRA and trans-
ferring surveillance of anal intraepithelial neoplasia
(AIN) to this less invasive outpatient-based modality.
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